Циркулюючий sST2 і прогноз кардіоваскулярних подій у ремісії множинної мієломи

M. O. Panasenko; B. B. Samura; S. Ya. Dotsenko

doi:10.14739/2310-1237.2022.2.259260

Authors

M. O. Panasenko Zaporizhzhia State Medical University, Ukraine, Ukraine https://orcid.org/0000-0002-2619-3846
B. B. Samura Zaporizhzhia State Medical University, Ukraine, Ukraine https://orcid.org/0000-0002-4311-1806
S. Ya. Dotsenko Zaporizhzhia State Medical University, Ukraine, Ukraine https://orcid.org/0000-0002-6584-4154

DOI:

https://doi.org/10.14739/2310-1237.2022.2.259260

Keywords:

sST2, cardiovascular events, multiple myeloma, survival, prognosis

Abstract

Aim. We aimed to evaluate the prognostic value of circulating sST2 for cumulative cardiovascular events in patients with multiple myeloma.

Materials and methods. Ninety seven patients with complete or partial remission of multiple myeloma were enrolled in the study. Observation period was up to 1 year. Blood samples for biomarkers measurements were collected. ELISA method for measurements of circulating level of sST2 was used.

Results. During observation period progression of multiple myeloma was proved in 25 patients, 5 persons were excluded for poor follow-up. 67 patients were included into statistical analysis. Thirty six cumulative clinical events occurred in 18 patients (26.9 %) within the follow-up, with their distribution being as follows: 2 deaths due to cardiovascular causes, 16 heart arrhythmias, 3 cardiac ischemic events, 1 stroke, 4 episodes of chronic heart failures and 10 hospital admissions due to cardiovascular events. 2 deaths were not related to cardiovascular pathology. Medians of levels of sST2 in free-events patients and patients with cardiovascular events were 24.17 ng/ml (95 % confidence interval (CI) = 12.87–27.48 ng/ml) and 47.57 ng/ml (95 % CI = 21.36–68.79 ng/ml) (Р < 0.01) respectively. In multivariate logistic regression analysis sST2 independently predicted cardiovascular events (odds ratio (OR) = 1.112; 95 % CI = 1.081–1.154; Р = 0.010) within 1 year of observation period.

Conclusions. Among patients with confirmed multiple myeloma at remission increased level of circulating sST2 associates with increased cumulative cardiovascular events during 1 year.

Author Biographies

M. O. Panasenko, Zaporizhzhia State Medical University, Ukraine

PhD student of the Department of Internal Diseases 3

B. B. Samura, Zaporizhzhia State Medical University, Ukraine

MD, PhD, DSc, Professor of the Department of Internal Diseases 3

S. Ya. Dotsenko, Zaporizhzhia State Medical University, Ukraine

MD, PhD, DSc, Professor, Head of the Department of Internal Disease 3

References

Bazyka, D. A., Gudzenko, N. A., Dyagil, I. S., Babkina, N. G., Chumak, V. V., Bakhanova, E. V., Paramonov, V. V., & Romanenko, A. Y. (2013). Multiple myeloma among Chornobyl accident clean-up workers - state and perspectives of analytical study. Problemy radiatsiinoi medytsyny ta radiobiolohii, (18), 169-172.

Osborne, T. R., Ramsenthaler, C., de Wolf-Linder, S., Schey, S. A., Siegert, R. J., Edmonds, P. M., & Higginson, I. J. (2014). Understanding what matters most to people with multiple myeloma: a qualitative study of views on quality of life. BMC cancer, 14, 496. https://doi.org/10.1186/1471-2407-14-496

De Stefano, V., Za, T., & Rossi, E. (2014). Venous thromboembolism in multiple myeloma. Seminars in thrombosis and hemostasis, 40(3), 338-347. https://doi.org/10.1055/s-0034-1370793

Gavriatopoulou, M., Musto, P., Caers, J., Merlini, G., Kastritis, E., van de Donk, N., Gay, F., Hegenbart, U., Hajek, R., Zweegman, S., Bruno, B., Straka, C., Dimopoulos, M. A., Einsele, H., Boccadoro, M., Sonneveld, P., Engelhardt, M., & Terpos, E. (2018). European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia, 32(9), 1883-1898. https://doi.org/10.1038/s41375-018-0209-7

Ewer, M. S., & Ewer, S. M. (2015). Cardiotoxicity of anticancer treatments. Nature reviews. Cardiology, 12(9), 547-558. https://doi.org/10.1038/nrcardio.2015.65

Heckmann, M. B., Doroudgar, S., Katus, H. A., & Lehmann, L. H. (2018). Cardiovascular adverse events in multiple myeloma patients. Journal of thoracic disease, 10(35), S4296-S4305. https://doi.org/10.21037/jtd.2018.09.87

Samura, B. B. (2012). Serdechno-sosudistye oslozhneniya polikhimioterapii onkogematologicheskikh zabolevanii: sovremennye podkhody k diagnostike [Cardiovascular complications of polychemotherapy of oncohematological diseases: modern approaches to diagnostics]. Zaporozhye Medical Journal, (6), 31-37. [in Russian].

Araujo-Gutierrez, R., Chitturi, K. R., Xu, J., Wang, Y., Kinder, E., Senapati, A., Chebrolu, L. B., Kassi, M., & Trachtenberg, B. H. (2021). Baseline global longitudinal strain predictive of anthracycline-induced cardiotoxicity. Cardio-oncology, 7(1), 4. https://doi.org/10.1186/s40959-021-00090-2

Yu, A. F., & Ky, B. (2016). Roadmap for biomarkers of cancer therapy cardiotoxicity. Heart (British Cardiac Society), 102(6), 425-430. https://doi.org/10.1136/heartjnl-2015-307894

Alexandre, J., Cautela, J., Ederhy, S., Damaj, G. L., Salem, J. E., Barlesi, F., Farnault, L., Charbonnier, A., Mirabel, M., Champiat, S., Cohen-Solal, A., Cohen, A., Dolladille, C., & Thuny, F. (2020). Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio-Oncology Guidelines. Journal of the American Heart Association, 9(18), e018403. https://doi.org/10.1161/JAHA.120.018403

Pudil, R., Mueller, C., Čelutkienė, J., Henriksen, P. A., Lenihan, D., Dent, S., Barac, A., Stanway, S., Moslehi, J., Suter, T. M., Ky, B., Štěrba, M., Cardinale, D., Cohen-Solal, A., Tocchetti, C. G., Farmakis, D., Bergler-Klein, J., Anker, M. S., von Haehling, S., Belenkov, Y., … Lyon, A. R. (2020). Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. European journal of heart failure, 22(11), 1966-1983. https://doi.org/10.1002/ejhf.2017

Ananthan, K., & Lyon, A. R. (2020). The Role of Biomarkers in Cardio-Oncology. Journal of cardiovascular translational research, 13(3), 431-450. https://doi.org/10.1007/s12265-020-10042-3

Hinrichs, L., Mrotzek, S. M., Mincu, R. I., Pohl, J., Röll, A., Michel, L., Mahabadi, A. A., Al-Rashid, F., Totzeck, M., & Rassaf, T. (2020). Troponins and Natriuretic Peptides in Cardio-Oncology Patients-Data From the ECoR Registry. Frontiers in pharmacology, 11, 740. https://doi.org/10.3389/fphar.2020.00740

Tan, L. L., & Lyon, A. R. (2018). Role of Biomarkers in Prediction of Cardiotoxicity During Cancer Treatment. Current treatment options in cardiovascular medicine, 20(7), 55. https://doi.org/10.1007/s11936-018-0641-z

Bracun, V., Aboumsallem, J. P., van der Meer, P., & de Boer, R. A. (2020). Cardiac Biomarkers in Patients with Cancer: Considerations, Clinical Implications, and Future Avenues. Current oncology reports, 22(7), 67. https://doi.org/10.1007/s11912-020-00930-x

Tseluyko, V. I., & Radchenko, O. V. (2018). Serdechno-sosudistye zabolevaniya u onkologicheskikh bol'nykh [Cardiovascular disease in oncological patients]. Liky Ukrainy, (3), 7-20. [in Russian]. https://doi.org/10.37987/1997-9894.2018.3(219)

Monsuez, J. J., Charniot, J. C., Vignat, N., & Artigou, J. Y. (2010). Cardiac side-effects of cancer chemotherapy. International journal of cardiology, 144(1), 3-15. https://doi.org/10.1016/j.ijcard.2010.03.003

Vianello, E., Dozio, E., Tacchini, L., Frati, L., & Corsi Romanelli, M. M. (2019). ST2/IL-33 signaling in cardiac fibrosis. The international journal of biochemistry & cell biology, 116, 105619. https://doi.org/10.1016/j.biocel.2019.105619

Huang, G., Zhai, J., Huang, X., & Zheng, D. (2018). Predictive value of soluble ST-2 for changes of cardiac function and structure in breast cancer patients receiving chemotherapy. Medicine, 97(38), e12447. https://doi.org/10.1097/MD.0000000000012447

Aula, H., Skyttä, T., Tuohinen, S., Luukkaala, T., Hämäläinen, M., Virtanen, V., Raatikainen, P., Moilanen, E., & Kellokumpu-Lehtinen, P. L. (2020). ST2 levels increased and were associated with changes in left ventricular systolic function during a three-year follow-up after adjuvant radiotherapy for breast cancer. Breast, 49, 183-186. https://doi.org/10.1016/j.breast.2019.12.001

Frères, P., Bouznad, N., Servais, L., Josse, C., Wenric, S., Poncin, A., Thiry, J., Moonen, M., Oury, C., Lancellotti, P., Bours, V., & Jerusalem, G. (2018). Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients. BMC cancer, 18(1), 102. https://doi.org/10.1186/s12885-018-4015-4

Mor-Avi, V., & Lang, R. M. (2012). Transthoracic Three-Dimensional Echocardiography. In Advanced Approaches in Echocardiography (pp. 1-20). Elsevier. https://doi.org/10.1016/b978-1-4377-2697-8.00001-8

Ministry of Health of Ukraine. (2015, November 2). Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi), tretynnoi (vysokospetsializovanoi) medychnoi dopomohy: mnozhynna miieloma [Unified clinical protocol of primary, secondary (specialized), tertiary (highly specialized) medical care "Multiple myeloma" (No. 710)]. [in Ukrainian]. https://dec.gov.ua/wp-content/uploads/images/dodatki/2015_710_MM/2015_710_YKPMD_MM.pdf